To test this hypothesis, MEF2 promoter activity was measured using a luciferase reporter assay in ovarian and breast cancer cell lines in the presence and absence of the SIK2 inhibitors ARN3236, ARN3261, or olaparib. This evidence concerns the gene SIK2 and breast carcinoma.